The receptor pharmacology I can follow; the in vivo translation is where I lose the thread.
The empirical answer seems settled. The explanation does not.
If the honest answer is that nobody knows, I would rather hear that than a plausible story.
What is the causal chain, and where does it stop being established?
Start with which indication and which dose, because the same molecule is licensed at different strengths for glycaemia and for weight and the trial evidence is separate.
Reconstitution and dilution arithmetic for research-grade lyophilised material is unaffected by any of this: concentration is content divided by diluent volume, and content is not the same as label claim.
Concretely, the STEP programme covers weight management, SUSTAIN covers glycaemia, SELECT covers cardiovascular outcomes in the without-diabetes population, FLOW covers kidney outcomes and ESSENCE covers MASH. Quoting across these is the most common citation error on this tag.
The albumin-binding acylation strategy is shared with liraglutide, which uses a shorter C16 chain and consequently has a daily rather than weekly profile.
Nothing here is medical advice.
Oral and injectable milligrams are not comparable. Exposures are.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsAnswering this needs the formulation. Weekly subcutaneous and daily oral are the same molecule with an order-of-magnitude difference in nominal dose.
Structurally: alanine at position 8 replaced with alpha-aminoisobutyric acid to resist dipeptidyl peptidase-4, lysine at position 34 replaced by arginine, and a C18 fatty diacid attached at position 26 through a short spacer. The last of those gives the albumin binding and the weekly half-life.
Oral semaglutide at 7 and 14 mg daily produces exposures comparable to lower weekly injectable doses, which is why the milligram figures are not comparable across routes.
A molecule being well studied does not make an unverified vial of it well characterised.
The C18 diacid and the position-8 substitution are the two facts worth memorising.
In practice, the relevant structural facts are the position-8 substitution blocking DPP-4 cleavage and the C18 diacid linker binding albumin.
The elimination half-life is approximately 165 to 184 hours — about a week — so steady state is reached after four to five weeks and any dose change takes that long to express itself fully.
Worth being precise here: independent testing services publish more results on this molecule than on any other in the market, which makes lot-level checking unusually practical here.
Published purity data on this molecule across the independent testing services is deep enough to make supplier-level comparison meaningful, which is not true of every compound.
One-week half-life means four to five weeks to steady state. Titration intervals follow from that.
Weight and glycaemic effects have different dose-response curves, which is why the licensed strengths differ by indication.
STEP-1 reported mean weight reduction of about fifteen per cent at 68 weeks on 2.4 mg against roughly two and a half per cent on placebo, in adults with obesity and without diabetes.
The caveat is that all of the trial evidence is for licensed product at controlled doses, and none of it transfers to material of unverified identity or content.
Name the trial programme with the claim: STEP, SUSTAIN, SELECT, FLOW and ESSENCE answer different questions.
This is the agent with the most published independent testing data in the research-compound market, which is a separate consideration from the clinical evidence.
Licensed weekly doses run 0.25, 0.5, 1.0, 1.7 and 2.4 mg depending on indication and product, with the 0.25 mg step being an initiation dose that is not intended to be therapeutic.
FLOW is the dedicated kidney-outcome trial and ESSENCE the MASH programme; both are semaglutide trials and neither is a tirzepatide trial.
Research-use material is not approved for human use in any jurisdiction.
If you are testing a lot, this is the molecule with the most published comparators to test it against.
edited 11 Oct 2025 by tobias_reint — expanded the table to cover the lower concentration
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.